The drugmaker’s Shingrix vaccine is hard to find in most states across the U.S. due to a high demand.
While the ramp-up may not curb the shortage right away, the drugmaker said it expects the accelerated production to help ease the shortage in the coming years.
“Shingrix should be an important growth driver for a number of years as we continue to expand capacity. More specifically, over the next two to three years, we plan to increase our annual capacity to levels of doses in the high-teens millions and build further from there,” Luke Miels, president of global pharmaceuticals at GSK, told Bio Process International.
More articles on supply chain:
Amazon to sell exclusive brand of consumer medical devices
The 1st flu treatment in decades, a diagnostic test for menopause & more: 5 latest FDA approvals
Senate Democrats question if FDA’s digital health pre-certification will ‘compromise public safety’
